Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

18th May 2018 (Last Updated August 12th, 2019 10:39)

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other investors.

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other investors.

Based in the US, Celsius Therapeutics is a biotech company engaged in translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer.

The company plans to use the proceeds towards the development of precision therapeutics.

Xenikos has raised $30m in a series B financing round led by Medicxi Ventures (UK) LLP and RA Capital Management as the lead financiers.

Dr Jon Edwards of Medicxi and Dr Jake Simson of RA Capital will be inducted as Xenikos’ board of directors, as part of the transaction.

Xenikos is a clinical-stage biopharmaceutical company based in Netherlands.

The company plans to use the proceeds for the clinical development and commercialisation of its steroid-resistant acute graft-versus-host disease (aGVHD) treatment, T-Guard.

US-based biotechnology company Nohla Therapeutics has raised $45m in a series B financing round.

Fidelity Management & Research Company and Celgene Corporation provided the finance in association with existing investors ARCH Venture Partners LP, 5AM Venture Management, Alexandria Venture Investments and AML Biotech Partners.

Nohla Therapeutics plans to use the proceeds for the completion of the ongoing phase II clinical trials of dilanubicel (NLA101), and for supporting phase III clinical trial and commercial manufacturing activities.

UK-based drug discovery biotech company CellCentric has raised $26m in a venture financing round led by Morningside Venture Investments.

"UK-based drug discovery biotech company CellCentric has raised $26m in a venture financing round led by Morningside Venture Investments."

The company will use the funds for testing its novel p300/CBP inhibitor in late-stage, treatment-resistant prostate cancer.

Singapore-based cell therapy company MediSix Therapeutics has raised 20m in a series A financing round led by Lightstone Ventures and participated by Temasek Holdings (Private) and Osage University Partners.

MediSix Therapeutics plans use the proceeds towards the development of a team to advance product development, and to initiate early pre-clinical studies.

US-based biotechnology company Ansun BioPharma has raised $85m in a series A financing round led by Sinopharm Healthcare Fund and Lilly Asia Ventures.

LYFE Capital, YuanMing Capital, Matrix Partners China, 3E Bioventures Capital, Oceanpine Healthcare Fund, Virtus Inspire Ventures, and Joincap Investment Management Cayman Islands also participated in the funding round.

The company will use the proceeds for the phase III clinical development of its experimental anti-viral medication, DAS181.

MEI Pharma (formerly Marshall Edwards) has signed a securities purchase agreement for the sale of its common stock and warrants to buy common stock worth $75m.

Vivo Capital and CAM Capital provided the lead finance for the transaction, along with New Enterprise Associates, Perceptive Advisors, The Biotechnology Value Fund, Boxer Capital of Tavistock Group and Amzak Health, as well as other new and existing investors.

MEI Pharma will issue 33 million priced at $2.273 a unit, as part of the agreement. Each unit will comprise one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $2.54.

Based in the US, MEI Pharma is an oncology company focused on the development of drugs for cancer treatment.

The company plans to use the proceeds for funding the clinical development of MEI-401, for the treatment of relapsed or refractory follicular lymphoma and for other general corporate purposes.

The company has appointed Stifel Financial Corp and Wells Fargo Securities as joint lead placement agents, and Oppenheimer & Co. and SunTrust Robinson Humphrey as lead co-placement agents for the transaction.

Laidlaw & Company has been appointed as co-placement agent, and BTIG as equity capital markets adviser.

Beam Therapeutics has raised up to $87m in a series A financing round from F-Prime Capital Partners and ARCH Venture Partners.

Based in the US, Beam is involved in the development of a suite of DNA base-editing technologies for the treatment of human disease.

The company has simultaneously entered multiple licensing agreements for base-editing technologies.